Company / SG&A Expense
Dianthus Therapeutics, Inc. /DE/ SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$34.3M
FY2025
5-year range
$6.7M / $34.3M
FY2021-FY2025
Trend
+89.1%
vs FY2024
Sector context
#179 of 213
Health Care
What the data says
Dianthus Therapeutics, Inc. /DE/'s sg&a expense of $34M is lower than 84% of companies in the Health Care sector (FY2025). Increased from $18M to $34M over the past 2 years.
Based on SEC 10-K filings.
$34M in FY2025 with a 5-year CAGR of +4.1%.
Increased from $18M to $34M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +72.0%
- 5-Year CAGR
- +4.1%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 213This company $34.3M Sector average $722.3M
▼
-95.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 89.1% year-over-year.
- Ranks #179 out of 213 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $34.3M | +89.1% |
| FY2024 | $18.2M | +0.0% |
| FY2023 | $18.2M | +169.3% |
| FY2022 | $6.7M | -75.9% |
| FY2021 | $27.9M | -0.6% |
| FY2020 | $28.1M | +18.2% |
| FY2019 | $23.8M | +27.6% |
| FY2018 | $18.6M | +137.9% |
| FY2017 | $7.8M | +124.6% |
| FY2016 | $3.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026